Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Use of Omalizumab in children in real clinical practice

Svetlana Zaytseva, Olga Zaytseva, Evelina Lokshina, Anna Tomilova, Olga Voronina, Olga Murtazaeva, Valery Mukhortykh, Irina Tsymbal
European Respiratory Journal 2021 58: PA3918; DOI: 10.1183/13993003.congress-2021.PA3918
Svetlana Zaytseva
1A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Federal Scientific Center for Children and Adolescents FMBA of Russia, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: zcv16@mail.ru
Olga Zaytseva
2A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evelina Lokshina
2A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anna Tomilova
3Federal Scientific Center for Children and Adolescents FMBA of Russia, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Voronina
3Federal Scientific Center for Children and Adolescents FMBA of Russia, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Olga Murtazaeva
2A.I. Yevdokimov Moscow State University of Medicine and Dentistry, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Valery Mukhortykh
3Federal Scientific Center for Children and Adolescents FMBA of Russia, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Irina Tsymbal
3Federal Scientific Center for Children and Adolescents FMBA of Russia, Moscow, Russian Federation
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Omalizumab, is the first targeted biologic therapeutic approved for the treatment of moderate and severe persistent uncontrolled asthma.

The aim: was to evaluate the clinical efficacy and safety of Omalizumab as additive treatment in children with severe uncontrolled asthma in real clinical practice.

Materials and methods: 23 children with severe uncontrolled atopic asthma aged from 6 to 18 years were included in this study. Examination included studying clinical data, level of total IgE, eosinophil count, skin tests, spirometry, chest X-ray, oxygen saturation monitoring, Childhood Asthma Control Test, Asthma Control Test. Patients were treated with Omalizumab once every four weeks. The duration of follow-up was from 1 to 5 years.

Results: The average age of the patients was 10.5 years±2.23 (6-11 years - 34.8%, 12-17 years - 65.2%). The duration of Omalizumab therapy was different: 1-2 years-39.1% children, 3-4 years-47.8% children, more than 5 years-13.1% children. 95.6% children have demonstrated positive dynamics for 12 months of therapy with Omalizumab. 82.6% patients achieved full control of asthma symptoms. 95.6% of patients had a decrease in the amount of antiinflammatory therapy (60.9% of patients changed therapy from LABA/ICS to monotherapy with ICS in medium doses, in 26.1% children the dose of ICS in the combined LABA/ICS was reduced from high to medium), decrease in total IgE, increased physical activity, reduced exacerbations. Serious adverse events were not observed.

Conclusions: Omalizumab is effective and safe in real clinical practice as addition to baseline therapy in severe uncontrolled asthma. It lowers the risk of exacerbations, achieves of control of asthma symptoms and improves quality of children’s life.

  • Children
  • Personalised medicine
  • Asthma - management

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3918.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Use of Omalizumab in children in real clinical practice
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Use of Omalizumab in children in real clinical practice
Svetlana Zaytseva, Olga Zaytseva, Evelina Lokshina, Anna Tomilova, Olga Voronina, Olga Murtazaeva, Valery Mukhortykh, Irina Tsymbal
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3918; DOI: 10.1183/13993003.congress-2021.PA3918

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Use of Omalizumab in children in real clinical practice
Svetlana Zaytseva, Olga Zaytseva, Evelina Lokshina, Anna Tomilova, Olga Voronina, Olga Murtazaeva, Valery Mukhortykh, Irina Tsymbal
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3918; DOI: 10.1183/13993003.congress-2021.PA3918
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Monoclonal antibody treatments for paediatric severe asthma–outcomes, attitudes and adherence
  • A systematic review of the proportion of adolescents recruited to RCTs of asthma treatments for adults and adolescents
  • Impact of COVID-19 side-effects on pediatric and adult patients with recurrent wheeze and asthma
Show more Paediatric asthma and allergy

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2023 by the European Respiratory Society